Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

Guillermo Garcia‐Manero, Lewis R. Silverman, Aref Al‐Kali et al.|The Lancet Oncology|2016

Cited by 172